The relative change (%) from T0 to T1 in IIEF-6 score ( p = 0.013), but not PSV, was significantly higher in l-ARG compared to placebo subgroups
Why It Happens So Often GLP-1s do an excellent job of reducing appetite and slowing digestion , but: They dont always address insulin resistance directly They often dont stimulate energy expenditure They rarely support nutrient partitioning or GIP/amylin balance The result
Wegovy (semaglutide) It was the first weekly injectable GLP-1 approved specifically for weight management in adults with a body mass index of 30 or higher, or 27 and above with at least one weight-related condition such as high blood pressure or type 2 diabetes
For the overwhelming majority of individuals pursuing meaningful, sustained weight reduction, semaglutide (or the more potent tirzepatide if greater weight loss is the goal) is the evidence-backed choice
CJC-1295, a long-acting GHRH analog, extends the bodys natural growth hormone pulse, while Ipamorelin, a selective Growth Hormone Releasing Peptide (GHRP), signals the pituitary to release GH without significantly affecting cortisol or prolactin
Key Points Question How do bariatric surgery and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) compare as obesity treatments regarding weight loss, ongoing costs, and health care utilization in a clinical setting
